Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.

Background: Remibrutinib (LOU064), an oral, highly selective Bruton tyrosine kinase inhibitor, offers fast disease control in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite treatment with second-generation H1 antihistamines. It is currently in phase 3 development for CSU.

Objective: We sought to evaluate long-term safety and efficacy of remibrutinib in patients with CSU inadequately controlled with H antihistamines.

[The impact of BMI on the course of the acute SARS-COV-2 infection and the risks that emerge during the first year after the hospital discharge. Subanalysis evidence of the AKTIV and AKTIV 2 registries].

Background: There is enough evidence of the negative impact of excess weight on the formation and progression of res piratory pathology. Given the continuing SARS-CoV-2 pandemic, it is relevant to determine the relationship between body mass index (BMI) and the clinical features of the novel coronavirus infection (NCI).

Aim: To study the effect of BMI on the course of the acute SARS-COV-2 infection and the post-covid period.

[ACTIV SARS-CoV-2 registry (Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients). Assessment of impact of combined original comorbid diseases in patients with COVID-19 on the prognosis].

Aim: Study the impact of various combinations of comorbid original diseases in patients infected with COVID-19 later on the disease progression and outcomes of the new coronavirus infection.

Materials And Methods: The ACTIV registry was created on the Eurasian Association of Therapists initiative. 5,808 patients have been included in the registry: men and women with COVID-19 treated at hospital or at home.

Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»).

Aim      To study the effect of regular drug therapy for cardiovascular and other diseases preceding the COVID-19 infection on severity and outcome of COVID-19 based on data of the ACTIVE (Analysis of dynamics of Comorbidities in paTIents who surVived SARS-CoV-2 infEction) registry.Material and methods  The ACTIVE registry was created at the initiative of the Eurasian Association of Therapists. The registry includes 5 808 male and female patients diagnosed with COVID-19 treated in a hospital or at home with a due protection of patients' privacy (data of nasal and throat smears; antibody titer; typical CT imaging features).

Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B-Cell Hematological Malignancies.

A fixed-dose subcutaneous (s.c.) formulation of the anti-CD20 antibody, rituximab, has been developed to address safety, infusion time, and patient comfort concerns relating to intravenous (i.

Comparative immunogenicity assessment of biosimilars.

The first anticancer biosimilars have entered clinical use, with many others under clinical development. Like all biologics, biosimilars may elicit unwanted immune responses that can significantly impact clinical efficacy and safety. Head-to-head immunogenicity assessment of biosimilars and their reference biologics should, therefore, be a critical component of a biosimilar's clinical development program.

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.

Background: Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5-6 h. A subcutaneous formulation could reduce patients' treatment burden and improve resource utilisation in health care. We aimed to show the pharmacokinetic non-inferiority of subcutaneous rituximab to intravenous rituximab in follicular lymphoma and to provide efficacy and safety data.

[CHANGES BLOOD GAS AND OF FREE RADICAL OXIDATION OF LIPIDS IN THE MYOCARDIUM DURING ADAPTATION TO PHYSICAL STRESS].

The article considers the changes of gas composition, acid-base blood balance, lipid peroxidation processes, and activity of the antioxidant defense system in rat myocardium in the course of adaptation to physical activity (swimming). It has been found out that during the first five days physical activity is accompanied by hypoxia, acidotic blood changes, and increase of lipid peroxidation processes in myocardium. Adaptation to swimming activity (15-30 days) leads to hypoxic and acidotic blood changes, and increases antioxidant defense system in myocardium.

[Candidatus "Jettenia moscovienalis" sp. nov., a New Species of Bacteria Carrying out Anaerobic Ammonium Oxidation].

A new species of bacteria oxidizing ammonium with nitrite under anoxic conditions was isolated from the activated sludge of a semi-industrial bioreactor treating digested sludge of the Kuryanovo wastewater treatment plant (Moscow, Russia). Physiological, morphological, and molecular genetic characterization of the isolate was carried out. The cells were ovoid (-0.

Exercise tests and BBB method for evaluation of motor disorders in rats after contusion spinal injury.

Contusion spinal injury of different severity was induced by the weight drop method in male rats by dropping standard weight from the heights of 6.5, 12.5, 25, and 50 mm on the spine after laminectomy at the Th9 level.

[Isothiorbamin possesses stress-protective action].

It was shown on a model of long-term stress induced by chronic electrostimulation of the ventromedial hypothalamus of rabbits that administration of isothiorbamin in the active periods of the experiment prevents hyperactivation of lipid peroxidation in the blood and myocardium by maintaining the activity of antioxidant enzymes. Isothiorbamin also causes an antiatherogenic effect on the blood lipid spectrum, raises the efficacy of the work of the heart and decreases the stressogenic ischemic disorders of the myocardium.

[Balanced vegetarian diet in combined rehabilitation of patients suffering from ischemic heart disease].

The clinical status of 30 patients suffering from ischemic heart disease, their serum lipids and other biochemical parameters, exercise tolerance were studied. 20 patients from the group were on a specially developed antiatherosclerosis vegetarian diet VA-1; the control group comprised 10 patients who had a mixed diet A-1. It is shown that the vegetarian diet used made it possible to normalize the serum lipid spectrum, the levels of the blood pressure, to increase the tolerance to exercise, to eliminate functional disturbances of the digestive system.

[Feasibility of correcting lipid metabolism in patients with cardiovascular diseases using a balanced vegetarian diet].

The spectrum of lipids in 20 patients with dyslipoproteinemia type IIa and IIb (group I and group II) was studied. The patients were treated for 24 days with a lactoovovegetarian diet used for the first time in the country. No drugs were employed.